Sucanon, an oral medication for type-2 diabetes, is a member of a class of diabetic medications called insulin sensitizers which help the body to make better usage of its own insulin to control blood sugar levels.
According to pre-clinical and clinical studies, Sucanon lowers blood sugar by increasing the muscle, fat and liver’s sensitivity to the body’s own naturally produced insulin.
Fero Industries chief operating officer Luis Lopez said the expansion of distribution has placed Sucanon and Sucanon related marketing material in almost three times as many retail stores and should continue to boost market awareness and acceptance of Sucanon as an OTC treatment for type-2 diabetes across Mexico.